FPRX Five Prime Therapeutics, Inc.

32.36
+0  (0%)
Previous Close 32.29
Open 32.39
Price To book 2.27
Market Cap 890.19M
Shares 27,509,000
Volume 291,754
Short Ratio 5.89
Av. Daily Volume 432,058

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 dose expansion phase initiated May 2016. Completion of enrollment announced April 10, 2017. Data due at ASCO June 4, 2017. Abstract 11078.
Cabiralizumab (FPA008)
Pigmented Villonodular Synovitis (PVNS)
Phase 1b NSCLC halted, mesothelioma to continue. Data due at ESMO 8-12 September 2017. Exact date TBC.
FP-1039
Mesothelioma cancer

Latest News

  1. Five Prime to Present Clinical Data at 2017 ASCO Annual Meeting
  2. Five Prime Therapeutics to Announce First Quarter 2017 Financial Results and Host Conference Call on May 4
  3. Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis (PVNS)
  4. Five Prime Presents Data on Unique Immuno-Oncology Discovery Research at the 2017 AACR Annual Meeting
  5. Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting
  6. Five Prime Presents Preclinical Research Data on Novel Tetravalent Anti-GITR Antibody at 2017 AACR Annual Meeting
  7. ETFs with exposure to Five Prime Therapeutics, Inc. : March 27, 2017
  8. Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  9. Five Prime Therapeutics Announces Executive Changes
  10. Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: 2016 By the Numbers : March 1, 2017
  11. Edited Transcript of FPRX earnings conference call or presentation 23-Feb-17 9:30pm GMT
  12. Five Prime Therapeutics posts 4Q loss
  13. Five Prime Announces Fourth Quarter and Full Year 2016 Financial Results
  14. Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call on February 23
  15. Five Prime Therapeutics to Present at the LEERINK Partners 6th Annual Global Healthcare Conference
  16. Five Prime to Present Preclinical Research Data at 2017 AACR Annual Meeting
  17. Cabiralizumab From Five Prime Therapeutics Inc (FPRX) Obtains Orphan Designation
  18. European Commission Grants Orphan Drug Designation to Cabiralizumab (FPA008) for Pigmented Villonodular Synovitis (PVNS)
  19. Blog Coverage Five Prime Announced Extension of Collaboration Agreement by Bristol-Myers Squibb
  20. Bristol-Myers Extends Deal with Five Prime Therapeutics